Form 4: Phio Pharmaceuticals Director Acquires 2,000 Shares of Common Stock

Director Curtis Lockshin acquired 2,000 shares of Phio Pharmaceuticals Corp. common stock on September 11, 2024, through a restricted stock unit grant.

Summary

• On September 11, 2024, Curtis Lockshin, a director of Phio Pharmaceuticals Corp., acquired 2,000 shares of common stock.
• The acquisition was made through a restricted stock unit grant, with the shares vesting on the first anniversary of the grant.
• The price per share was $0.
• Following the transaction, Lockshin beneficially owns 2,000 shares of common stock, including shares underlying unvested restricted stock units.
• The transaction was reported on September 12, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock acquisition by a director, which can be seen as a slightly positive sign of confidence, but it's not a major event.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Key Dates

Keywords

Phio Pharmaceuticals, Director, Curtis Lockshin, Stock Acquisition, Restricted Stock Unit, Beneficial Ownership, Form 4